Skip to content
Extreme Investor Network
  • Contact Us
  • Privacy Policy

PBMs

CVS CEO Justifies PBMs While Criticizing Drug Manufacturers for ‘Monopolistic’ Behavior

February 13, 2025
CVS CEO defends PBMs, accuses drugmakers of 'monopolistic' practices

Understanding the Controversy Surrounding CVS Health and Pharmacy Benefit Managers In recent discussions within the healthcare community, one topic has come under intense scrutiny: pharmacy benefit managers (PBMs). David Joyner, the newly appointed CEO of … Read more

Categories Business News Tags behavior, CEO, Criticizing, CVS, drug, justifies, Manufacturers, Monopolistic, PBMs

Source says FTC will sue PBMs over drug prices, including insulin

July 10, 2024
FTC to sue PBMs over drug prices including insulin, source says

Federal Trade Commission Planning to Sue Major U.S. Health Companies Over Drug Pricing Practices The Federal Trade Commission (FTC) is gearing up to file lawsuits against three of the largest U.S. health companies over their … Read more

Categories Business News Tags drug, FTC, Including, insulin, PBMs, Prices, Source, Sue

Categories

Recent Posts

  • CVS CEO Justifies PBMs While Criticizing Drug Manufacturers for ‘Monopolistic’ BehaviorFebruary 13, 2025
  • Reduce Debt or Risk an Economic CrisisFebruary 13, 2025
  • JPMorgan Maintains Sell Rating on Super Micro Despite Positive Company OutlookFebruary 13, 2025
  • EPA Discarded Billions Before Trump’s PresidencyFebruary 13, 2025
  • Riot Platforms (RIOT) Restructures Board and Investigates AI PotentialFebruary 13, 2025
  • Goldman Sachs Acquires Bitcoin and Ethereum as Crypto ETF Investments Surpass $2 BillionFebruary 13, 2025
  • Daily Outlook for Gold (XAU) and Silver (XAG): PPI Report Approaches as Gold Approaches $2,920 ResistanceFebruary 13, 2025
  • Barclays Q4 2024 Earnings ReportFebruary 13, 2025
  • ESPN Host Stephen A. Smith “Wouldn’t Be Against” Running for U.S. PresidentFebruary 13, 2025
  • Amazon Set for a Strong Rebound, Chart Analysis RevealsFebruary 13, 2025

Archives

© 2025 Extreme Investor Network

Usermaven | Website analytics and product insights